Growth Metrics

Veracyte (VCYT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $68.3 million.

  • Veracyte's Operating Expenses rose 200.47% to $68.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.6 million, marking a year-over-year increase of 222.18%. This contributed to the annual value of $282.0 million for FY2024, which is 1061.12% down from last year.
  • Latest data reveals that Veracyte reported Operating Expenses of $68.3 million as of Q3 2025, which was up 200.47% from $95.0 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Operating Expenses registered a high of $100.3 million during Q4 2023, and its lowest value of -$35.1 million during Q4 2022.
  • For the 5-year period, Veracyte's Operating Expenses averaged around $73.0 million, with its median value being $77.1 million (2021).
  • As far as peak fluctuations go, Veracyte's Operating Expenses tumbled by 14410.5% in 2022, and later skyrocketed by 38543.17% in 2023.
  • Veracyte's Operating Expenses (Quarter) stood at $79.7 million in 2021, then tumbled by 144.1% to -$35.1 million in 2022, then surged by 385.43% to $100.3 million in 2023, then decreased by 25.64% to $74.6 million in 2024, then decreased by 8.37% to $68.3 million in 2025.
  • Its last three reported values are $68.3 million in Q3 2025, $95.0 million for Q2 2025, and $76.6 million during Q1 2025.